J&J to emphasize cancer drugs and stop much of its vaccine research; Is the flu shot market a slam dunk for mRNA vaccines?

Taking stock of the drug industry, from the lab to the medicine chest

December 5, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Daniel Hulshizer/AP STAT+ | J&J to emphasize cancer drugs and stop much of its vaccine research The disclosures were made in an interview ahead of an investor meeting that Reed is leading on Tuesday. By Matthew Herper Is the flu shot market a slam dunk for mRNA vaccines? Experts aren't so sure Experts see some significant benefits of applying mRNA technology to the production of flu vaccine — but also some serious challenges. By Helen Branswell STAT+ | New CAR-T company, Brainchild Bio, will focus first on brain tumors in children Researchers have hit a wall developing cell therapies for children with cancer. A new Seattle startup is trying to fix that. By Jason Mast Alex Wong/Getty Images STAT+ | Cancer drug shortages won't get better under Biden's latest plan President Biden's new plan to curb drug shortages won't help with cancer drug shortages, an administration official confirmed. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser